Storys zum Thema Forschung
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- Ein Dokumentmehr
Bosch Healthcare Solutions GmbH
Bosch and Randox: Strategic partnership brings highly multiplexing PCR to the point of care / BioMEMS technology enables fully automated, simultaneous testing for hundreds of genetic characteristics in just a few minutes
Waiblingen (ots) - - Bosch and Randox Laboratories Ltd. enter partnership for Vivalytic analysis platform to jointly invest around 150 million euros. - First test to feature novel BioMEMS technology will be a highly multiplexing sepsis IVD grade test. Bosch has agreed on a strategic partnership with Randox ...
mehrDr. Reddy's subsidiary betapharm, and Theranica launch Nerivio® in Germany to provide patients with drug-free migraine treatment
mehrARTCLINE successfully completes capital increases of EUR 4.4 million
Rostock, Germany (ots) - Today ARTCLINE GmbH announced the successful completion of two further capital increases. In addition to the founders, in particular family offices from Germany participated in the first capital increase of EUR 0.8 million. In addition, a convertible loan from investors was transferred to equity, so that a second capital increase of EUR 3.6 ...
mehr2022 Marked a Record for German R&D Investments
Berlin (ots) - EUR 121.4 billion was spent in Germany on reasearch and development - more than ever before in a single year. According to the Federal Statistical Office, the amount of money devoted to R&D rose by seven percent in 2022, reaching an all-time high. The figures include commercial, university and non-university research. R&D investments by businesses grew by eight percent, reaching EUR 81.8 billion. That's ...
mehr- 4
FDX Fluid Dynamix and Fraunhofer IPK to Collaborate with Lonza on Novel Nanoparticle Formulation Technology Platform FDmiX
mehr Research Success in Rare Disease / RHEACELL receives positive signal for accelerated stem cell development program in rare ‚Butterfly Disease‘
mehrLTS Lohmann Therapie-Systeme AG
First product based on LTS’ Sorrel(TM) wearable drug delivery platform launched in the US
mehrWhat Our Genetic Information Tells Us About Type 2 Diabetes Risk and Complications
mehrUniversità degli studi di Milano - Bicocca
Early Smartphone Use in Children? Two Studies Highlight Long-Term Consequences
Milan (ots) - A group of researchers from the University of Milano-Bicocca and SUPSI, by means of longitudinal data provided by INVALSI (Italian Institute for the Evaluation of the Education System), has confirmed that early smartphone usage before the age of 12 does not bring benefits. Instead, it is associated with lower digital skills, higher problematic smartphone ...
mehrThe ocean – a climate champion? How to boost marine carbon dioxide uptake
mehrLTS Lohmann Therapie-Systeme AG
LTS receives $4.3 Million grant for the development of contraceptive Microneedle Array Patches
mehrAntech launches first comprehensive veterinary diagnostics offering in the UK, including a new state-of-the-art reference laboratory
Warwick, England, 7 Nov. 2023 (ots/PRNewswire) - Antech to offer UK veterinary professionals a complete and flexible diagnostics portfolio spanning reference labs, in-house diagnostics, imaging and software Antech, the full-service veterinary diagnostics business that is part of the Science & Diagnostics division of ...
mehr- 2
PIONEER+ becomes Big Data Platform for Prostate Cancer of the EAU's UroEvidenceHub
mehr - 3
EU Provides 1 Mio. to Researchers to Advance Personalised Oncology
Ein Dokumentmehr canSERV Releases Open Call for Transnational Service Provision
Ein DokumentmehrHearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial
Tübingen, Germany (ots) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic otoprotectant ...
mehrHearing loss company Acousia Therapeutics to present key learnings and data from lead development programs at US and European meetings in August and September
Tübingen, Germany (ots) - Acousia Therapeutics GmbH to share key learnings and data from its lead candidate development programs — clinical stage ACOU085 and late preclinical stage ACOU082 — during four presentations at industry and research meetings from August 29 to September 5. From August 29–31, Acousia ...
mehrLife Science Factory to Open a New Location in Munich in 2024
mehrGrünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration
Aachen, Germany and Tokyo, Japan (ots) - - The Joint Venture Collaboration includes a portfolio of 13 brands across six therapeutic areas, with the majority of revenue resulting from pain management medicines - The new enterprise will be branded as Grünenthal Meds. Grünenthal owns a 51 percent majority share and ...
mehrPatientGPT from Semalytix Will Replace Six Months of Evidence & Insight Generation in Life Science with Seconds
mehrRHEACELL announces “First Patient In”: EB-Haus in Salzburg, Austria starts pivotal study for stem cell therapy for severe forms of Epidermolysis bullosa that is longed for by those affected
mehrEmpowering the Future of Pain Relief Research: Recipients of the 2023 EFIC-Grünenthal Grant Announced
Brussels/Aachen (ots) - - Three promising early-career scientists have been awarded the prestigious EFIC-Grünenthal Grant (E-G-G) 2023. - The E-G-G funds innovative research projects to advance understanding of pain and improve the lives of people suffering from pain. The European Pain Federation EFIC® and the ...
mehrBirth weight and head circumference predict IQ and motor performance at 4 years of age
mehrGrünenthal’s resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee
Aachen (ots) - - Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain. - Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid ...
mehrFraunhofer-Institut für Sichere Informationstechnologie SIT
AI against money laundering
mehrAmicogen and Lysando: Novel approach for the treatment of mastitis in dairy cows
mehrGrünenthal and King’s College London collaborate to develop human induced pluripotent stem cell-based microfluidic cultures for pain research
Aachen, Germany and London, England (ots) - - Dr Ramin Raouf from King's College London and Grünenthal strive to develop reliable microfluidic culture models relevant for pain research based on human induced pluripotent stem cell-derived neurons - Grünenthal has expertise in developing human induced pluripotent ...
mehrLTS Lohmann Therapie-Systeme AG
LTS expands into large molecule drug delivery with the acquisition of the Sorrel wearable injection device business
Andernach, Germany (ots) - LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches (“TTS”), Oral Thin Films (“OTF”) and Micro Array Patches (“MAP”) announces the signing of the ...
mehrGenialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response
BOSTON, LAUSANNE & LJUBLJANA, Slovenia (ots) - Debiopharm Innovatoin Fund & Taiwania Capital co-lead financing round for Genialis to propel drug development, diagnostics and treatment planning through AI/ML-enabled platform with a biology-first approach Genialis, a computational precision medicine company unraveling complex biology to find new ways to address disease, ...
mehr